The affordability programs are well worth observing. Novo Nordisk’s price savings applications may well evolve as Levels of competition heats up. The Norwegian Medicines Agency claimed in January 2023 it wouldn't subsidise the drug, stating the price would be much too significant in relation for the documented well being consequences. https://evansb886pfq6.wikiconversation.com/user